Sign In
Last checked at 
2 Nov 2020 07:00
Syncona Limited
Directorate Change
02 November 2020
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announces Ellen Strahlman has retired as a Non-Executive Director with effect from 2 November 2020.
Melanie Gee, Chair of Syncona Limited, said: "The Board and management team would like to thank Ellen for her expert support and significant contribution to the Company and Syncona life science business since its inception in 2013. Ellen has been a non-executive Director with both Syncona Partners and Syncona Limited and her expertise in global product development and commercialization has been invaluable to draw on as the Company has progressed its strategy of founding and building global leaders in life science. We wish her well for the future."
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
Follow the stocks
